| 000 | 01554 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517132007.0 | ||
| 264 | 0 | _c20170822 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1720-8386 | ||
| 024 | 7 |
_a10.1007/s40618-016-0595-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCasagrande, A | |
| 245 | 0 | 0 |
_aRemission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study. _h[electronic resource] |
| 260 |
_bJournal of endocrinological investigation _cMay 2017 |
||
| 300 |
_a523-528 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAcromegaly _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aCabergoline |
| 650 | 0 | 4 |
_aErgolines _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOctreotide _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aWithholding Treatment |
| 700 | 1 | _aBronstein, M D | |
| 700 | 1 | _aJallad, R S | |
| 700 | 1 | _aMota, J I | |
| 700 | 1 | _aTabet, A | |
| 700 | 1 | _aAbucham, J | |
| 773 | 0 |
_tJournal of endocrinological investigation _gvol. 40 _gno. 5 _gp. 523-528 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40618-016-0595-5 _zAvailable from publisher's website |
| 999 |
_c26728519 _d26728519 |
||